Results · Apr-Jun 2026
Oxygenta Pharmaceutical Q1 FY27 results
Sales grew 144% to ₹37 crore from ₹15.1 crore in Apr-Jun 2025.
Operating profit was ₹0.55 crore, an operating margin of 1.5% (up 46.6 points from a year ago).
The net loss narrowed to ₹2.1 crore from ₹6.1 crore.
Against Jan-Mar 2026: sales −25%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 37.0 | 15.1 | +144% |
| Operating profit (EBITDA) | 0.5 | -6.8 | n/m |
| Operating margin | 1.5% | −45.1% | +46.6 pts |
| Net profit | -2.1 | -6.1 | loss narrows |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.